Gefitinib Inhibits Invasion and Metastasis of Osteosarcoma via Inhibition of Macrophage Receptor Interacting Serine-Threonine Kinase 2.
Animals
Antineoplastic Agents
/ pharmacology
Apoptosis
Bone Neoplasms
/ drug therapy
Cell Proliferation
Female
Gefitinib
/ pharmacology
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Macrophages
/ drug effects
Male
Mice
Mice, Inbred BALB C
Mice, Knockout
Mice, Nude
Neoplasm Invasiveness
Osteosarcoma
/ drug therapy
Receptor-Interacting Protein Serine-Threonine Kinase 2
/ antagonists & inhibitors
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
Journal
Molecular cancer therapeutics
ISSN: 1538-8514
Titre abrégé: Mol Cancer Ther
Pays: United States
ID NLM: 101132535
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
17
09
2019
revised:
18
12
2019
accepted:
26
03
2020
pubmed:
7
5
2020
medline:
29
4
2021
entrez:
7
5
2020
Statut:
ppublish
Résumé
Most patients with osteosarcoma have subclinical pulmonary micrometastases at diagnosis. Mounting evidence suggests that macrophages facilitate metastasis. As the EGFR has been implicated in carcinoma-macrophage cross-talk, in this study, we asked whether gefitinib, an EGFR inhibitor, reduces osteosarcoma invasion and metastatic outgrowth using the K7M2-Balb/c syngeneic murine model. Macrophages enhanced osteosarcoma invasion
Identifiants
pubmed: 32371577
pii: 1535-7163.MCT-19-0903
doi: 10.1158/1535-7163.MCT-19-0903
doi:
Substances chimiques
Antineoplastic Agents
0
RIPK2 protein, human
EC 2.7.11.1
Receptor-Interacting Protein Serine-Threonine Kinase 2
EC 2.7.11.1
Ripk2 protein, mouse
EC 2.7.11.1
Gefitinib
S65743JHBS
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1340-1350Informations de copyright
©2020 American Association for Cancer Research.